Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
Gregory Lawrence Beatty
No relevant relationships to disclose
Peter J. O'Dwyer
Research Funding - Incyte
Jason Clark
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jack G Shi
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Robert Charles Newton
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Richard Schaub
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Janet Maleski
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Lance Leopold
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Thomas Gajewski
Research Funding - Incyte